Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. by Murakami, Takashi et al.
UCLA
UCLA Previously Published Works
Title
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived 
orthotopic xenograft (PDOX) nude-mouse model.
Permalink
https://escholarship.org/uc/item/1c8916w0
Journal
Oncotarget, 8(22)
ISSN
1949-2553
Authors
Murakami, Takashi
Li, Shukuan
Han, Qinghong
et al.
Publication Date
2017-05-01
DOI
10.18632/oncotarget.15823
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Oncotarget35630www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 22), pp: 35630-35638
Recombinant methioninase effectively targets a Ewing’s 
sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-
mouse model
Takashi Murakami1,2,3, Shukuan Li1, Qinghong Han1, Yuying Tan1, Tasuku Kiyuna1, 
Kentaro Igarashi1, Kei Kawaguchi1, Ho Kyoung Hwang1, Kentaro Miyake1,2,3, Arun 
S. Singh4, Scott D. Nelson5, Sarah M. Dry5, Yunfeng Li5, Yukihiko Hiroshima3, 
Thinzar M. Lwin2, Jonathan C. DeLong2, Takashi Chishima3, Kuniya Tanaka3, 
Michael Bouvet2, Itaru Endo3, Fritz C. Eilber6 and Robert M. Hoffman1,2
1 AntiCancer, Inc., San Diego, California, USA
2 Department of Surgery, University of California, San Diego, California, USA
3 Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
4 Division of Hematology-Oncology, University of California, Los Angeles, California, USA
5 Department of Pathology, University of California, Los Angeles, California, USA
6 Division of Surgical Oncology, University of California, Los Angeles, California, USA
Correspondence to: Robert M. Hoffman, email: all@anticancer.com
Correspondence to: Fritz C. Eilber, email: fceilber@mednet.ucla.edu
Keywords: recombinant methioninase, patient-derived orthotopic xenograft, Ewing’s sarcoma, recalcitrant cancer, nude mice
Received: December 15, 2016 Accepted: January 11, 2017 Published: March 01, 2017
Copyright: Murakami et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Methionine dependence is due to the overuse of methionine for aberrant 
transmethylation reactions in cancer. Methionine dependence may be the only general 
metabolic defect in cancer. In order to exploit methionine dependence for therapy, our 
laboratory previously cloned L-methionine α-deamino-γ-mercaptomethane lyase [EC 
4.4.1.11]). The cloned methioninase, termed recombinant methioninase, or rMETase, 
has been tested in mouse models of human cancer cell lines. Ewing’s sarcoma is 
recalcitrant disease even though development of multimodal therapy has improved 
patients’outcome. Here we report efficacy of rMETase against Ewing’s sarcoma in 
a patient-derived orthotopic xenograft (PDOX) model. The Ewing’s sarcoma was 
implanted in the right chest wall of nude mice to establish a PDOX model. Eight 
Ewing’s sarcoma PDOX mice were randomized into untreated control group (n = 4) and 
rMETase treatment group (n = 4). rMETase (100 units) was injected intraperitoneally 
(i.p.) every 24 hours for 14 consecutive days. All mice were sacrificed on day-15, 24 
hours after the last rMETase administration. rMETase effectively reduced tumor growth 
compared to untreated control. The methionine level both of plasma and supernatants 
derived from sonicated tumors was lower in the rMETase group. Body weight did not 
significantly differ at any time points between the 2 groups. The present study is the 
first demonstrating rMETase efficacy in a PDOX model, suggesting potential clinical 
development, especially in recalcitrant cancers such as Ewing’s sarcoma.
INTRODUCTION
Methionine dependence is the enhanced requirement 
of methionine for cancer cells compared to normal cells. 
Methionine dependence may be the only known general 
and very widespread metabolic defect in cancer [1].
Research Paper
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Out of 23 cell lines derived from diverse types 
of human tumors, 11 did not grow at all in methionine-
depleted, homocysteine-containing (MET-HCY+) medium 
and were absolutely methionine-dependent, whereas 3 
grew only slightly in this medium. Many of the cancer cell 
lines tested have little else in common other than the fact 
that they are methionine-dependent. The high frequency of 
occurrence of methionine dependence in diverse types of 
human cancer cells indicated that methionine dependence 
could be an important aspect of oncogenic transformation. 
Normal unestablished cell strains thus far characterized 
grow well in MET-HCY+ medium [2, 3]. 
Twenty-one different human tumor cell lines 
(4 lung, 4 colon, 4 kidney, 4 melanoma, 3 CNS, and 
2 prostate) and normal cell strains were treated with 
recombinant methioninase (rMETase) in vitro. rMETase 
had a mean IC50 for the cancer cells, which was one order 
of magnitude lower than that for normal cell strains [4]. 
Many lines of evidence indicated that the malignant 
and transformed cells synthesize large amounts of 
methionine endogenously despite their requirement for 
elevated exogenous methionine [1]. 
In a diverse set of human cancer cell lines, all were 
found to be defective in at least one aspect of methionine 
metabolism, giving rise to the possibility of a general 
metabolic defect in cancer [5]. 
We observed that cancer cells have enhanced overall 
rates of transmethylation compared to normal human 
fibroblasts. The overuse of methionine for enhanced 
and unbalanced transmethylation may be the basis of 
the methionine dependence of cancer cells. The overuse 
of methionine by cancer cells is termed the “Hoffman 
effect”. The alteration of such a fundamental process 
as transmethylation in cancer may be indicative of its 
importance in the oncogenic process [6]. 
Rare cells from methionine-dependent cancer cell 
lines regained the normal ability to grow in MET−HCY+ 
medium [7]. Methionine-independent revertants had 
much lower basal transmethylation rates than parental 
methionine-dependent cell lines. These results further 
suggested that methionine dependence is due to an 
increase in the rate of transmethylation reactions [7]. 
By selecting for methionine independence, it is 
possible to select for cells, which became less malignant, 
indicating further a linkage between altered methionine 
metabolism and oncogenic transformation [7-9]. 
rMETase arrested growth of HCT 15 and HT29 
colon cancer in nude mice for 1 week after treatment 
termination. Colo 205 and SW 620 colon cancer were 
partially arrested by rMETase [10]. 
Methionine dependence was also found to occur in 
fresh patient tumors histocultured on Gelfoam® [11]. 
Our laboratory pioneered the patient-derived 
orthotopic xenograft (PDOX) nude mouse model with 
the technique of surgical orthotopic implantation (SOI) 
[12, 13]. PDOX models were established from patients 
with colon [14-16], pancreatic [17-28], breast [29], 
ovarian [30], lung [31] and stomach cancer [32], and 
mesothelioma [33] in our laboratory, resulting in primary 
and metastatic tumor growth very similar to that of the 
patient [32]. Recently, PDOX models of sarcoma have 
been developed [34-38], as well as for cervical cancer [39-
41] and melanoma [42-44] in our laboratory. 
Ewing’s sarcoma is a rare and aggressive 
malignancy. Previously, a tumor from a patient with a 
Ewing’s sarcoma with cyclin-dependent kinase inhibitor 
2A/B (CDKN2A/B) loss and FUS-ERG fusion was 
implanted in the right chest wall of nude mice to establish 
a PDOX model. The Ewing’s sarcoma PDOX model was 
sensitive to the CDK4/6 inhibitor, palbociclib, and the 
IGF-R inhibitor, linsitinib. The PDOX tumor was resistant 
to doxorubicin as was the patient [37].  
The present report demonstrates the efficacy of 
rMETase on the PDOX model of Ewing’s sarcoma. 
RESULTS AND DISCUSSION
Established Ewing’s sarcoma PDOX tumor 
recapitulates the original patient tumor
The PDOX tumor in the right chest wall of nude 
mice histologically recapitulated the original patient tumor 
(Figure 1) [37]. 
Plasma L-methionine level was effectively 
decreased by rMETase intraperitoneal injection 
(i.p.) in nude mice
Plasma L-methionine levels decreased after 6 to 
12 hours after i.p. administration of rMETase (Figure 
2). Twenty-four hours after administration, plasma 
L-methionine level was still decreased to 37% of initial 
levels. 
Ewing’s sarcoma PDOX tumor growth was 
suppressed by rMETase treatment
The tumor volume ratio in the rMETase-treated 
group was significantly smaller from day 10 to 15 
compared to the untreated control mice (P < 0.05) (Figure 
3). Tumor weight was also significantly smaller in 
rMETase-treated group (60.6 ± 10.6 mg) than in control 
group (86.1 ± 6.8 mg) (P < 0.01) (Figure 3). Mouse body 
weight was not significantly reduced in the rMETase 
group (Figure 4).
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Plasma and tumor-extract L-methionine was 
reduced by rMETase
Plasma L-methionine level in the rMETase-treated 
Ewing’s sarcoma PDOX (15.0 ± 8.8 nmol/ml) trended to 
be lower than in the untreated control (26.0 ± 8.1 nmol/
ml). L-methionine levels were reduced in the rMETase-
treated tumors (9.5 ± 11.3 nmol/mg protein) compared to 
the untreated control tumor (27.5 ± 12.2 nmol/mg protein) 
(Figure 5). Although changes in methionine levels did 
not reach statistical significance, they show a definite 
trend of depletion. It should be noted that the methionine 
levels were measured 24 hours after the last rMETase 
administration during which time MET levels could have 
increased from both endogenous synthesis and mouse 
Figure 1: Histology of original and PDOX Ewing’s sarcoma. A. Four weeks after orthotopic tumor implantation, PDOX tumors 
grew in the right chest wall (yellow dotted line). Upper right panel shows the resected PDOX tumor. Scale bars: 5 mm. H&E staining of the 
PDOX tumor B. and original patient tumor C. Scale bars: 50 μm [37]..
Figure 2: Pharmacodynamics study of plasma L-methionine level after intraperitoneal injection of rMETase. Nude 
mice without tumors were used for the analysis. Plasma L-methionine levels were measured before injection, and 3, 6, 12, and 24 hours 
after i.p. injection of rMETase. The percentage of initial L-methionine level is indicated at each time point. L-methionine was measured by 
HPLC as described in the Materials and Methods. N = 1. 
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Figure 4: Response of Ewing’s sarcoma PDOX mouse body weight to rMETase. Line graphs show mouse body weight of each 
group. Error bars: ± 1 SD. N = 4 for each group. 
Figure 3: Response of Ewing’s sarcoma PDOX to rMETase. A. Line graph shows tumor volume ratio of both groups. Tumor 
volume ratio tumor volume at indicated tunes relative  to tumor volume at day 0 in rMETase-treated group was significantly smaller from 
day10 to 15 compared to control. B. Bar graph shows resected tumor weight. Tumor weight was also significantly less in the rMETase-
treated group than in the control group. **P < 0.01, *P < 0.05. Error bars: ± 1 SD. SD, standard deviation. N = 4 for each group. 
Figure 5: Plasma and Ewing’s sarcoma PDOX tumor L-methionine levels at termination of the experiments. Bar graphs 
show A. plasma L-methionine level and B. Tumor L-methionine level standardized by tumor protein concentration. Both plasma and tumor 
L-methionine levels in the rMETase-treated animals were lower than control. Error bars: ± 1 SD. N = 4 for each group.
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chow. 
The present study has important implications since 
it is the first in vivo efficacy study of rMETase on a patient 
tumor, in this case, a PDOX model of Ewing’s sarcoma, a 
recalcitrant cancer. The present results and previous results 
indicating the generality of methionine dependence, and 
the linkage of methionine dependence to fundamental 
properties of malignancy, suggest that rMETase is a 
specific tumor-targeting agent that may be applicable to 
the treatment of multiple types of cancer [1-10, 45-50]. 
Further rMETase efficacy studies in PDOX models of 
various tumor types should serve as a bridge to the clinic. 
Previously-developed concepts and strategies of 
highly selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [51-57].
CONCLUSIONS
The present study has demonstrated efficacy of 
rMETase on a Ewing’s sarcoma PDOX model. This is 
the first experiment in which rMETase was tested on a 
patient-derived tumor in a mouse model. The results 
indicate the potential of rMETase in the clinic. However, 
important questions remain including whether rMETase 
can shrink tumors as monotherapy or whether combination 
with chemotherapy would be more effective. Combination 
of rMETase and cell-cycle-specific drugs could take 
advantage of the late-S/G2 cell arrest observed in cancer 
cells after methionine depletion [45-48, 58]. Another 
question remains what is the long-term fate of cancer cells 
arrested in late-S/G2 by rMETase such as whether the cells 
eventually undergo apoptosis or necrosis. 
MATERIALS AND METHODS 
Mice
Athymic male nu/nu nude mice (AntiCancer Inc., 
San Diego, CA), 4-6 weeks old, were used in this study. 
All animal studies were conducted in accordance with the 
principals and procedures outlined in the Guide for the 
Care and Use of Laboratory Animals, 8th edition under 
Public Health Service Assurance Number A3873-1. 
Animals were housed with no more than 5 per cage and 
housed in a barrier facility on a high efficiency particulate 
arrestance (HEPA)-filtered rack under standard conditions 
of 12-hour light/dark cycles. The animals were fed an 
autoclaved laboratory rodent diet. 
Patient-derived Ewing’s sarcoma tumor and 
establishment of PDOX
A female patient was diagnosed with Ewing’s 
sarcoma in the right chest wall. She underwent surgery in 
the Department of Surgery, University of California, Los 
Angeles (UCLA). Written informed consent was obtained 
from the patient, and the Institutional Review Board (IRB) 
of UCLA approved this experiment. After mice were 
anethesized, a 7-mm skin incision was made on the right 
chest wall. A single tumor fragment (4 mm3) was then 
implanted orthotopically into the layer between pectoral 
muscle and intercostal muscle in right chest wall of nude 
mouse to establish the PDOX model [37]. 
rMETase production
The pAC-1 rMETase high-expression clone was 
used for rMETase production. The fermentation procedure 
for host E.coli cells and the purification protocol for 
rMETase were the same as previously described: rMETase 
was purified by 3 different steps using columns of DEAE 
Sepharose FF and Sephacryl S-200HR, and ActiClean 
Etox, which is designed for eliminating endotoxin [49]. 
Treatment dose and schedule
The PDOX model mice (n = 8) were randomized 
into an rMETase treatment group (n = 4) and an untreated 
control group (n = 4) when tumor volume reached 60 mm3. 
rMETase (100 units) was administered by intraperitoneal 
injection, every 24 hours for 14 consecutive days. Blood 
samples were collected at 24 hours after the last rMETase 
administration at which point the mice were sacrificed. 
Tumor length, width, and mouse body weight were 
measured twice a week. Tumor volume was calculated 
by the following formula: Tumor volume (mm3) = 
length (mm) × width (mm) × width (mm) × 1/2. Tumor 
volume ratio was defined as the ratio of volume on each 
measurement day relative to day 0. 
Plasma L-methionine levels
A mouse without tumor was treated with 100 
units rMETase by i.p. administration. Fifty μl blood was 
collected from the retro-orbital plexus with heparinated 
capillary tubes before treatment and 3, 6, 12, and 24 hours 
after treatment. Plasma was obtained from the blood 
by centrifugation at 4,000 rpm for 5 minutes. Plasma 
L-methionine levels were measured with an HPLC 
(Hitachi L-6200A Intelligent pump; Hitachi, Ltd., Tokyo, 
Japan) after derivatization of serum amino acids with the 
fluoraldehyde reagent OPA as described previously [49, 
50]. L-methionine levels are shown as the percentage of 
the initial plasma L-methionine level.
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Tumor protein level measurement
To standardize tumor L-methionine measurements, 
tumor protein levels were measured. Briefly, each PDOX 
tumor was placed in phosphate buffered saline (PBS) (1 
ml). Tumors were sonicated on ice for 30 seconds and 
subsequently centrifuged at 12,000 rpm for 10 minutes. 
Supernatants were diluted to concentrations ranging 
from 200 to 1500 μl/ml. Protein assay reagent (Bio-Rad, 
Hercules, CA) was prepared as a 4-fold dilution and 
added to each tube with the sonicated tumor supernatents, 
then absorbance of 595 nm was measured with a U-2000 
spectorophotometer (Hitachi, Tokyo, Japan). Protein 
levels were calculated from the standard curve obtained 
by protein standard, bovine serum albumin (BSA).
Tumor L-methionine level analysis at termination
Tumor supernatants obtained from the above-
described sonication procedure were precipitated by 
acetonitrile. Using the same procedure described above, 
L-methionine levels were determined as nmol/ml with 
the HPLC procedure described above [50]. Standardized 
L-methionine levels were calculated using the following 
formula: standardized L-methionine level (nmol/mg 
protein) = L-methionine level (nmol/ml) / protein level 
(mg protein/ml).
Histological analysis
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (5 μm) were deparaffinized in xylene 
and rehydrated in an ethanol series. Hematoxylin and 
eosin (H&E) staining was performed according to a 
standard protocol. Histological analysis was performed 
with a BHS system microscope (Olympus Corp., Tokyo, 
Japan). Images were acquired with INFINITY ANALYZE 
software (Lumenera Corporation, Ottawa, Canada) [37].
Statistical analysis
SPSS statistics version 21.0 was used for all 
statistical analyses (IBM, New York City, NY, USA). 
Significant differences for continuous variables were 
determined using the Student’s t-test. Both line graphs 
and bar graphs express mean values. An error bar shows 
standard deviation (SD). A probability value (P) was 
calculated between the control and treatment groups. P < 
0.05 was considered statistically significant. 
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